Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy
Despite the significant progress of modern anticancer therapies, multiple myeloma (MM) is still incurable for the majority of patients. Following almost three decades of development, chimeric antigen receptor (CAR) T-cell therapy now has the opportunity to revolutionize the treatment landscape and m...
Main Authors: | Ewelina Grywalska, Barbara Sosnowska-Pasiarska, Jolanta Smok-Kalwat, Marcin Pasiarski, Paulina Niedźwiedzka-Rystwej, Jacek Roliński |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/4/983 |
Similar Items
-
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
by: Wan-Hong Zhao, et al.
Published: (2018-12-01) -
Recent updates on CAR T clinical trials for multiple myeloma
by: Quande Lin, et al.
Published: (2019-11-01) -
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
by: Renée Poels, et al.
Published: (2021-01-01) -
Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
by: Yaru Feng, et al.
Published: (2021-01-01) -
CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer
by: Dominika Bębnowska, et al.
Published: (2020-06-01)